<?xml version='1.0' encoding='utf-8'?>
<document id="24689515"><sentence text="Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam."><entity charOffset="98-107" id="DDI-PubMed.24689515.s1.e0" text="midazolam" /></sentence><sentence text="AZD7325 is a selective gamma-amino-butyric acid (GABAA )α2, 3 receptor modulator"><entity charOffset="23-47" id="DDI-PubMed.24689515.s2.e0" text="gamma-amino-butyric acid" /></sentence><sentence text=" The aims of this analysis were to develop population pharmacokinetic (PPK) models of AZD7325 and midazolam and to assess the induction effect of AZD7325 on CYP3A4 with midazolam as a substrate"><entity charOffset="86-93" id="DDI-PubMed.24689515.s3.e0" text="AZD7325" /><entity charOffset="98-107" id="DDI-PubMed.24689515.s3.e1" text="midazolam" /><entity charOffset="169-178" id="DDI-PubMed.24689515.s3.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.24689515.s3.e0" e2="DDI-PubMed.24689515.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24689515.s3.e0" e2="DDI-PubMed.24689515.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24689515.s3.e0" e2="DDI-PubMed.24689515.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24689515.s3.e1" e2="DDI-PubMed.24689515.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24689515.s3.e1" e2="DDI-PubMed.24689515.s3.e2" /></sentence><sentence text="" /><sentence text="Drug-drug interaction data of AZD7325 and midazolam from 24 healthy subjects were available for model development"><entity charOffset="42-51" id="DDI-PubMed.24689515.s5.e0" text="midazolam" /></sentence><sentence text=" PPK models were developed in a sequential manner using NONMEM" /><sentence text=" Both AZD7325 and midazolam pharmacokinetics were described by two-compartment models, and a transit compartment absorption model and a first-order absorption model were applied for the absorption of AZD7325 and midazolam, respectively"><entity charOffset="6-13" id="DDI-PubMed.24689515.s7.e0" text="AZD7325" /><entity charOffset="18-27" id="DDI-PubMed.24689515.s7.e1" text="midazolam" /><entity charOffset="200-207" id="DDI-PubMed.24689515.s7.e2" text="AZD7325" /><entity charOffset="212-221" id="DDI-PubMed.24689515.s7.e3" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e0" e2="DDI-PubMed.24689515.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e0" e2="DDI-PubMed.24689515.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e0" e2="DDI-PubMed.24689515.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e0" e2="DDI-PubMed.24689515.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e1" e2="DDI-PubMed.24689515.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e1" e2="DDI-PubMed.24689515.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e1" e2="DDI-PubMed.24689515.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e2" e2="DDI-PubMed.24689515.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24689515.s7.e2" e2="DDI-PubMed.24689515.s7.e3" /></sentence><sentence text=" The induction of CYP3A by AZD7325 was described by a transit enzyme model, where the elimination of midazolam was proportionally linked to the enzyme amount"><entity charOffset="101-110" id="DDI-PubMed.24689515.s8.e0" text="midazolam" /></sentence><sentence text=" Simulations were performed to predict dosing regimens to account for the induction of CYP3A4" /><sentence text="" /><sentence text="The population estimates for AZD7325 clearance, intercompartmental clearance, central and peripheral volume were 36, 29·2 L/h, 169 and 392 L, respectively, with interindividual variability (IIV) of 35% and 24% for clearance and central volume" /><sentence text=" Midazolam clearance, intercompartmental clearance, central and peripheral volume were estimated to be 62·7, 34·7 L/h, 133 and 146 L, respectively, with 43% IIV for clearance"><entity charOffset="1-10" id="DDI-PubMed.24689515.s12.e0" text="Midazolam" /></sentence><sentence text=" The estimated mean transit time for induction of the CYP3A4 enzyme was 197 h, with 57% IIV" /><sentence text="" /><sentence text="The PPK models developed adequately described the clinical observation of AZD7325-mediated CYP3A4 enzyme induction with midazolam as a probe"><entity charOffset="120-129" id="DDI-PubMed.24689515.s15.e0" text="midazolam" /></sentence><sentence text=" The model could provide basis for the rational dosing of AZD7325 in clinical practice" /><sentence text="" /></document>